Sandhofer Str. 116
68305 Mannheim, de
+1 (608) 218-7623
ATLAS Biolabs GmbH Joins Roche NimbleGen's Certified Service Provider Program for Targeted Enrichment
"The decision to join the Roche NimbleGen CSP Program was a logical extension of our portfolio. Our customers are looking at targeted genomic sequencing and we wanted to provide them with a set of elite solutions for the necessary enrichment" said Prof. Dr. Peter Nurnberg, CEO of ATLAS Biolabs GmbH.
"Roche NimbleGen welcomes the latest addition, ATLAS Biolabs GmbH, to our CSP family for Sequence Capture. ATLAS Biolab's close ties with key opinion leaders across several key market segments in Germany, in addition to their established academic excellence, will further strengthen our position as a leader in the targeted resequencing market and drive future growth of the Roche NimbleGen business and service channel in Europe," said Jay Schiestle, Vice President of Manufacturing for Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com. For more information about 454 Life Sciences, please visit www.454.com.
About ATLAS Biolabs GmbH
ATLAS Biolabs GmbH, with offices and laboratories in Berlin and Cologne, is a leading European service provider of several highthroughput microarraybased applications such as targeted genomic enrichment, genomewide expression analysis, SNP analysis, and CGH analysis, followed by high performance data processing and bioinformatics. The company's main mission is to deliver consistent, highquality genomic services to their customers through the use of streamlined, formalized business processes. ATLAS Biolabs' commitment to quality includes the certification DIN EN ISO 9001:2008, which is a common global quality management standard.
For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, GS FLX TITANIUM, and NIMBLEGEN are trademarks of Roche.
Other brands or product names are trademarks of their respective holders.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.